

STOCK INFORMATION

OTC Symbol:	PGCX
Recent Price:	\$0.51
52-Wk Range:	\$.002 – \$1.10
Shares Outstanding:	80.1 Mil
Estimated Public Float:	15.0 Mil
Market Cap:	\$40.9 Mil
Fiscal Year End:	June 30

BUSINESS SUMMARY

PanGenex (OTC: PGXC) develops, manufactures and distributes nutraceutical and dietary supplements, Over-the Counter (OTC) topical drugs and personal care products focused on cardiovascular health and wellness. PanGenex's patented, trademarked and proprietary formulations address the root cause of some the world's most prevalent diseases affecting aging populations. Many products contain the purest grade of nutraceuticals available anywhere without a prescription. PanGenex voluntarily submits its products without incidence to the US Food and Drug Administration.

PanGenex's products are manufactured at state-of-the-art, Certified Good Manufacturing Practices (cGMP)-compliant facilities. Products are sold direct to health care practitioners in the U.S., Canada, South America and Europe, high-end retail and direct-to-consumer over the Internet.

NICHE MARKET

“The accumulation of calcium in coronary arteries, and not cholesterol, more accurately predicts a future heart attack or other heart trouble.” The New England Journal of Medicine, March 2008

Defined as the “abnormal hardening or thickening of tissue in the arteries,” Soft Tissue Calcification (STC) can be caused by a plurality of factors. STC is linked to over 50% of chronic diseases and presently affects 196 Million Americans. PanGenex is a global niche player in the \$538 Million the STC treatment market, with a primary focus on cardiac health & wellness. STC is associated with life-threatening conditions including: Alzheimer's, Arthritis, Cancer, Diabetes, Cardiovascular Disease, Kidney Stones, Lyme Disease and Scleroderma.



INVESTMENT HIGHLIGHTS

- **Explosive Market Demand** – Worldwide sales of nutraceuticals are expected to increase at a compound annual growth rate of 7.4% to \$176.7 Billion in 2013.*
- **Scientifically formulated products** are backed by a decade of research and development
- **Widespread applications** address the root cause of over 50% of the diseases listed as the nation's leading causes of death.
- **78 Million Aging “Baby Boomers”** - More than 70% of those aged 55 and over take a daily supplement
- **Patent-pending product lines** target both the nutraceutical and pharmaceutical industries
- **Partnerships with top medical doctors** and life science professionals
- **Strong physician relationships** and referral network to propel growth
- **Global distribution channels** including North and South America, and Europe
- **Renowned cardiologists** on the Board of Directors and Scientific Advisory Board

*Source: 2008 BBC Research

INNOVATIVE PRODUCT SUITE

PanGenex's flagship products, Calci-Clear™, Lipideme™ and Omeganol™, are showing strong physician and end user acceptance in the marketplace.

Calci-CLEAR™ is scientifically formulated to address the mechanisms involved in the development of STC. Calci-CLEAR is a 3-step system containing over 50 high quality ingredients that combine to help bind and remove calcium crystals and promote healthy mineral balance and bone health.



Preliminary results from PanGenex's 100 patient, double blind, placebo-based clinical trial show significant reductions in total coronary arterial calcium after merely five months of taking Calci-CLEAR AM & PM. The product is currently being recommended and/or sold by health care professionals in greater than 20 physician states in the U.S. and individual customers around the world are using Calci-CLEAR. The product is also being evaluated in clinical testing by the Cardiovascular Institute of the South.

Lipedeme™ is a revolutionary product and the first to combine the triglyceride-lowering power of Omega-3 (fatty acids) with the cholesterol-lowering ability of phytosterols and tocotrienols — plus the free-radical fighting capacity of Coenzyme Q10 (“CoQ10”).



Omeganol™ is the industry's first nutraceutical to combine the highest concentration of Omega-3 (86% pure extract) with the cholesterol balancing activity of tocotrienols and heart-healthy CoQ10. High cholesterol (above 200 mg/mL) affects nearly one out of every three Americans and has shown to be an independent, high risk factor for heart disease.



BULLISH CONSUMER TRENDS

Seventy-eight million Americans fall into what is commonly known as the “Baby Boomer” generation. Today's Boomers are in their mid-40s to 60s, generally have high disposable income, prefer high-quality, branded merchandise, and are interested in maintaining a healthy lifestyle. The aging Baby Boomer demographic is PGCX's primary target market, followed by those aged 65 and up.

Research shows that people are living longer and healthier lives. By 2025, statistics indicate 20% of all Americans will be considered senior citizens. As the nation's health care costs skyrocket, nutraceuticals (a nutrition/pharmaceutical combination that extracts medicinal benefits from all-natural ingredients) are rapidly gaining popularity as an affordable, easily accessible and conceived better-for-you alternative to prescriptive medicine. In fact, about half of all

Americans take a daily supplement. That number jumps to over 70% for those aged 55 years and up, providing PGCX long-term growth potential.

MULTIPLE SALES CHANNELS

PanGenex markets products through four primary sales channels:

- Tele-Sales and Repeat/Referral Business in the United States, Canada, South America, Europe and beyond.
- Internet Marketing, including company owned Websites www.PanGenex.com, www.HeartHealthyWorld.com and www.Calgenex.com; Search Engine Optimization (SEO) techniques, viral, e-newsletter and e-mail marketing
- Distributors and physician resellers who buy in bulk and resell to retail outlets, physicians, wellness clinics, chiropractors and more
- Proprietary online portals given to select retailers to boost sales and improve customer satisfaction by using an online ordering system and “Drop Ship” direct to customers.

IMPRESSIVE LEADERSHIP

James Mosbaugh, COO/Vice President, brings over 10 years of formulation chemistry experience to PanGenex. Mosbaugh previously served as project manager and intellectual property consultant of Nanobac Pharmaceuticals (OTCBB: NNBP). Mosbaugh has extensive expertise in the formulation of topical OTC drugs, personal care products, nutraceutical products, and sol gel chemistry.

Mindy Rippetto, Director of Operations, has 13 years of retail and operational management experience. Prior to joining subsidiary Calgenex in 2007, Rippetto was an executive leading some of the nation's top-selling brands including Abercrombie & Fitch, Ann Taylor and Victoria's Secret.

John Stanton, Chairman of the Board, MBA, CPA, is a business executive of over 35 years. Prior to founding Calgenex in 2006, Stanton served at Ernst & Young and as President and CEO of Cast-Crete Corp.

Ronald Caputo, MD, FACS, FSCAI, Director, is Director of Cardiology Research at St. Joseph's Hospital and Assistant Clinical Professor of Medicine at SUNY-HSC, in Syracuse, New York.

Steven Joseph Yakubov, MD, FACC, FASCI, Advisor, an interventional cardiologist, is Director of the Cardiac Catheterization Laboratory at Marion General Hospital and Medical Director of the MidWest Cardiology Research Foundation.

Mark Turco, MD, FACC, FSCAI, Advisor, is an interventional cardiologist, Director of the Center of Cardiac & Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland and Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD.

GROUNDLOOR OPPORTUNITY

PanGenex is one of the few companies in the world to target the root cause of many of today's most prevalent diseases and conditions affecting the aging Baby Boomer and elder populations. The Company has a proven track record in the commercialization of innovative nutraceutical and healthcare products. With additional financing, PGCX is poised to dramatically increase its global marketing and distribution channels for its patented and proprietary products. With revenues under \$200,000 in fiscal 2009, PGCX represents a groundfloor investment opportunity with explosive upside potential. □

CONTACT

PanGenex Corporation
2409 N Falkenburg Road
Tampa, Florida 33619
Phone: 866-579-1188
Fax: 813-623-5625
Email: invest@pangenex.com
Websites: www.PanGenex.com
www.Calgenex.com
www.HeartHealthyWorld.com
Informative Blog available at:
www.managecholesterolnaturally.com

DISCLAIMER

This report contains "forward-looking statements," which are statements related to future and not historical facts. Forward-looking statements can be identified by such words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Forward looking statements regarding the Company's goals, plans, projections and guidance regarding its financial position, results of operations, market position, pending and potential, future acquisitions and business strategy are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, but are not limited to, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) cost of obtaining financing, (e) ability to complete acquisitions and dispositions and the risks associated therewith, and (f) ability to retain key personnel. These factors, as well as additional factors, could affect these forward-looking statements. The company takes no responsibility to update forward-looking statements, including earnings outlook. The statements in this report have not been evaluated by the Food and Drug Administration. Products is not intended to diagnose, treat, cure or prevent any disease.

###